Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Lineage Cell Therapeutics, Inc. (LCTX : AMEX)
 
 • Company Description   
Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are in clinical stage. Lineage Cell Therapeutics Inc., formerly known as BioTime Inc., is based in Carlsbad, California.

Number of Employees: 61

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.25 Daily Weekly Monthly
20 Day Moving Average: 759,674 shares
Shares Outstanding: 169.73 (millions)
Market Capitalization: $212.16 (millions)
Beta: 1.89
52 Week High: $3.00
52 Week Low: $1.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.93% 15.99%
12 Week -13.19% -2.44%
Year To Date -48.98% -37.67%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2173 SALK AVENUE SUITE 200
-
CARLSBAD,CA 92008
USA
ph: 442-287-8990
fax: 510-521-3389
ir@lineagecell.com http://www.lineagecell.com
 
 • General Corporate Information   
Officers
Brian M. Culley - Chief Executive Officer
Kevin Leon Cook - Chief Financial Officer
Deborah Andrews - Director
Dipti Amin - Director
Don M. Bailey - Director

Peer Information
Lineage Cell Therapeutics, Inc. (CORR.)
Lineage Cell Therapeutics, Inc. (RSPI)
Lineage Cell Therapeutics, Inc. (CGXP)
Lineage Cell Therapeutics, Inc. (BGEN)
Lineage Cell Therapeutics, Inc. (GTBP)
Lineage Cell Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 53566P109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 169.73
Most Recent Split Date: 10.00 (3.00:1)
Beta: 1.89
Market Capitalization: $212.16 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.17 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.49
Price/Cash Flow: -
Price / Sales: 23.01
EPS Growth
vs. Year Ago Period: 33.33%
vs. Previous Quarter: 20.00%
Sales Growth
vs. Year Ago Period: 1,239.39%
vs. Previous Quarter: 336.42%
ROE
03/31/22 - -27.43
12/31/21 - -26.95
09/30/21 - -17.41
ROA
03/31/22 - -19.66
12/31/21 - -21.36
09/30/21 - -15.78
Current Ratio
03/31/22 - 3.33
12/31/21 - 2.37
09/30/21 - 7.77
Quick Ratio
03/31/22 - 3.33
12/31/21 - 2.37
09/30/21 - 7.77
Operating Margin
03/31/22 - -311.86
12/31/21 - -694.26
09/30/21 - -561.20
Net Margin
03/31/22 - -528.23
12/31/21 - -983.92
09/30/21 - -339.99
Pre-Tax Margin
03/31/22 - -530.57
12/31/21 - -996.78
09/30/21 - -404.73
Book Value
03/31/22 - 0.50
12/31/21 - 0.54
09/30/21 - 0.71
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.02
Debt-to-Capital
03/31/22 - 0.03
12/31/21 - 0.03
09/30/21 - 1.56
 

Powered by Zacks Investment Research ©